Zacks: Analysts Expect The Beauty Health Company (NASDAQ:SKIN) Will Post Quarterly Sales of $68.89 Million

Brokerages forecast that The Beauty Health Company (NASDAQ:SKINGet Rating) will post $68.89 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for Beauty Health’s earnings, with the lowest sales estimate coming in at $62.30 million and the highest estimate coming in at $73.17 million. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Beauty Health will report full year sales of $328.22 million for the current financial year, with estimates ranging from $325.30 million to $331.90 million. For the next fiscal year, analysts anticipate that the company will report sales of $408.07 million, with estimates ranging from $395.80 million to $428.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Beauty Health.

Beauty Health (NASDAQ:SKINGet Rating) last posted its earnings results on Tuesday, February 22nd. The company reported $0.01 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.04. The firm had revenue of $77.90 million for the quarter, compared to analysts’ expectations of $70.90 million. The company’s revenue for the quarter was up 106.1% compared to the same quarter last year.

Several analysts have recently issued reports on the company. William Blair assumed coverage on Beauty Health in a research report on Friday, January 7th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. assumed coverage on Beauty Health in a research report on Friday, March 11th. They issued an “overweight” rating and a $24.00 price objective on the stock. DA Davidson upped their price objective on Beauty Health from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, February 23rd. Benchmark upped their price objective on Beauty Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, March 14th. Finally, Zacks Investment Research upgraded Beauty Health from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research note on Saturday, February 26th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $27.90.

A number of large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. increased its stake in Beauty Health by 47.5% during the third quarter. PNC Financial Services Group Inc. now owns 1,962 shares of the company’s stock worth $50,000 after acquiring an additional 632 shares during the last quarter. Baird Financial Group Inc. boosted its position in shares of Beauty Health by 3.9% in the fourth quarter. Baird Financial Group Inc. now owns 64,449 shares of the company’s stock worth $1,557,000 after buying an additional 2,400 shares during the period. Emfo LLC purchased a new stake in shares of Beauty Health in the third quarter worth about $78,000. Logan Capital Management Inc. purchased a new stake in shares of Beauty Health in the third quarter worth about $78,000. Finally, Lindbrook Capital LLC purchased a new stake in shares of Beauty Health in the fourth quarter worth about $74,000. Institutional investors own 62.99% of the company’s stock.

Shares of NASDAQ:SKIN traded down $0.14 on Tuesday, hitting $15.16. The company had a trading volume of 1,045,338 shares, compared to its average volume of 1,633,488. The company has a quick ratio of 12.63, a current ratio of 13.09 and a debt-to-equity ratio of 2.41. Beauty Health has a 52-week low of $9.71 and a 52-week high of $30.17. The business has a 50 day moving average of $16.53 and a 200 day moving average of $20.78.

Beauty Health Company Profile (Get Rating)

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums.

Featured Stories

Get a free copy of the Zacks research report on Beauty Health (SKIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Beauty Health (NASDAQ:SKIN)

Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.